Home
Halfdan Sørbye's picture

Halfdan Sørbye

Professor
  • E-mailHalfdan.Sorbye@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2020. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncologica. 417-426.
  • 2020. Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Scientific Reports. 1-9.
  • 2019. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 54-62.
  • 2019. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology. 1088-1095.
  • 2019. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. 1-14.
  • 2019. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology. 376-388.
  • 2019. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocrine-Related Cancer. 227-239.
  • 2019. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncologica. 1-8.
  • 2019. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Medicine. 3623-3635.
  • 2018. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinology and metabolism clinics of North America (Print). 683-698.
  • 2018. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer. 1609-1616.
  • 2018. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology (MO).
  • 2018. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. British Journal of Surgery.
  • 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer. 35-45.
  • 2018. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 807-815.
  • 2017. Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv. 1-11.
  • 2017. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology. 1682-1689.
  • 2017. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer.
  • 2017. Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery. 580-589.
  • 2017. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surgery.
  • 2017. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLOS ONE. 1-13.
  • 2017. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer. 26-35.
  • 2017. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLOS ONE. 1-15.
  • 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology. 196-200.
  • 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology. 281-294.
  • 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 266-280.
  • 2017. Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer. 1271-1278.
  • 2017. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocrine-Related Cancer. 427-443.
  • 2016. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. OncoTarget. 59441-59457.
  • 2016. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. OncoTarget. 41948-41958.
  • 2016. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology. 1721-1728.
  • 2016. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. 22 pages.
  • 2016. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. OncoTarget. 75013-75022.
  • 2016. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer. 647-656.
  • 2016. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica. 881-885.
  • 2016. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 186-194.
  • 2016. Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy. 12-22.
  • 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • 2015. Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much? Acta Oncologica. 437-446.
  • 2015. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer. 2708-2717.
  • 2015. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology (WJSO).
  • 2015. Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical decision making. 255-265.
  • 2015. Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clinical colorectal cancer. 170-176.
  • 2015. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer. 2470-2477.
  • 2015. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLOS ONE.
  • 2014. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. PLOS ONE.
  • 2014. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 1284-1297.
  • 2014. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer. 912-919.
  • 2013. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 152-160.
  • 2013. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 1208-1215.
  • 2013. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology. 2354-2360.
  • 2012. Small Cell Lung Cancer in a 14-Year-Old Girl. Journal of Pediatric Hematology/Oncology. E86-E88.
  • 2012. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery. 534-539.
  • 2012. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 1755-1762.
  • 2012. Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer. 189-194.
  • 2012. Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer.
  • 2012. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer. 435-441.
  • 2012. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine. 2189-2197.
  • 2011. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 61-71.
  • 2011. Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 4617-4622.
  • 2010. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica. 740-756.
  • 2009. Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. Cancer. 4679-4687.
  • 2008. Prognostic clinical factors in metastatic colorectal cancer. Advances in Gastrointestinal Cancers. 6-8.
  • 2008. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet. 1007-1016.
  • 2008. Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Annals of Oncology. 1154-1159.
  • 2008. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology. 909-914.
  • 2005. SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • 2004. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • 2004. Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • 2003. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • 2003. Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • 2003. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • 2002. Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. Journal of Surgical Research. 167-178.
  • 2002. Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. Digestive Diseases and Sciences. 2354-2369.
  • 2002. Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. Japanese Journal of Cancer Research. 484-494.
  • 2001. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • 1999. Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2063-2075.
  • 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • 1998. Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2012-2020.
  • 1997. Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. Digestive Diseases and Sciences. 1765-1774.
  • 1993. Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. Digestive Diseases and Sciences. 1243-1250.
Report
  • 2007. Health economic evaluation of bevacizumab for metastatic colorectal cancer. 23/2007. 23/2007. .
Academic lecture
  • 2015. Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer.
  • 2005. A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
Editorial
  • 2012. Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used? Acta Oncologica. 819-821.
Reader opinion piece
  • 2019. Ekspertpanel for ny vurdering ved alvorlig sykdom. Tidsskrift for Den norske legeforening. 2 pages.
Short communication
  • 2008. Surgery vs surgery and chemotherapy for colorectal liver metastases. The Lancet. 203.
Doctoral dissertation
  • 1994. Penetration of carcinogens into normal and damaged gastric mucosa.
Academic chapter/article/Conference paper
  • 2014. Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. 10 pages.
  • 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer. 4 pages.
  • 2009. Endokrine svulster. 9 pages.
  • 2008. The use of Chemotherapy for Neuroendocrine Tumors. 6 pages.
  • 1999. Antimetabolitter. 20 pages.
Abstract
  • 2019. Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology. iv131-iv131.
  • 2018. Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. Annals of Oncology. v109-v109.
  • 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • 2013. Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). Pancreas. 382-382.
  • 2012. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. Journal of Clinical Oncology. 1 pages.
  • 2012. Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. Journal of Clinical Oncology. 1 pages.
  • 2012. Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. Journal of Clinical Oncology. 1 pages.
  • 2012. Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. Annals of Oncology. 18-18.
  • 2012. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Journal of Clinical Oncology. 1 pages.
  • 2012. AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. Annals of Oncology. 188-188.
  • 2010. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. Annals of Oncology. 9-9.
  • 2006. Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 146S-146S.
  • 2005. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 253S-253S.
Poster
  • 2014. Development and validation of a Norwegian model for colorectal cancer.
  • 2003. Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer.
Errata
  • 2016. Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). European Journal of Cancer. 208-209.
Academic literature review
  • 2020. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). R67-R77.
  • 2018. Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. 115-124.
  • 2016. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. 11-24.
  • 2014. Gastroenteropancreatic high-grade neuroendocrine carcinoma. 2814-2823.
  • 2009. Positronemisjonstomografi ved nevroendokrine svulster. 1474-1477.
  • 2008. Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. 194-197.

More information in national current research information system (CRIStin)